Luteolin inhibits migration of human glioblastoma U-87 MG and T98G cells through downregulation of Cdc42 expression and PI3K/AKT activity

Molecular Biology Reports

Volumn 40, Issue 9, 2013, Pages 5315-5326

  Cheng, Wen Yu ^a,b,e   Chiao, Ming Tsang ^b   Liang, Yea Jiuen ^b   Yang, Yi Chin ^b   Shen, Chiung Chyi ^a,b,c,d,e   Yang, Chiou Ying ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Cdc42; Glioblastoma; Luteolin; Migration; PI3K AKT; Proteasome degradation

Indexed keywords

FLAVONOID; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN CDC42; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN FUNCTION; TUMOR INVASION;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; DNA PRIMERS; GENE EXPRESSION REGULATION; HUMANS; LUTEOLIN; NEOPLASM INVASIVENESS; PSEUDOPODIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84883275639     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2632-1     Document Type: Article

References (45)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683-2710
2. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD, de Vries HE (2004) Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 200:1667-1672
3. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ et al (1999) Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. British J Pharmacol 128:999-1010
4. Theoharides TC (2009) Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflam 6:29
5. Zhao Y, Yang G, Ren D, Zhang X, Yin Q, Sun X (2010) Luteolin suppresses growth and migration of human lung cancer cells. Mol Biol Rep 38:1115-1119
6. Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J (2009) Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther 8:1684-1691
7. Auyeung KK, Ko JK (2010) Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell. Invest New Drugs 28:1-13
8. Ashokkumar P, Sudhandiran G (2009) Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/beta-catenin pathway. Invest New Drugs 29:273-284
9. Manthey JA, Guthrie N (2002) Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 50:5837-5843
10. Markaverich BM, Vijjeswarapu M, Shoulars K, Rodriguez M (2010) Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J Steroid Biochem Mol Biol 122:219-231
11. Choi EM, Lee YS (2010) Luteolin suppresses IL-1beta-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW982. Food Chem Toxicol 48:2607-2611
12. Cazarolli LH, Zanatta L, Alberton EH, Figueiredo MS, Folador P, Damazio RG et al (2008) Flavonoids: cellular and molecular mechanism of action in glucose homeostasis. Mini Rev Med Chem 8:1032-1038
13. Kim DI, Lee TK, Lim IS, Kim H, Lee YC, Kim CH (2005) Regulation of IGF-I production and proliferation of human leiomyomal smooth muscle cells by Scutellaria barbata D. Don in vitro: isolation of flavonoids of apigenin and luteolin as acting compounds. Toxicol Appl Pharmacol 205:213-224
14. Fang J, Zhou Q, Shi XL, Jiang BH (2007) Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 28:713-723
15. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C et al (2004) Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64:7936-7946
16. Lopez-Lazaro M, Willmore E, Austin CA (2007) Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod 70:763-767
17. Cantero G, Campanella C, Mateos S, Cortes F (2006) Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagenesis 21:321-325
18. Sim GS, Lee BC, Cho HS, Lee JW, Kim JH, Lee DH et al (2007) Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase activity in UVA-irradiated human dermal fibroblast. Arch Pharm Res 30:290-298
19. Lin Y, Shi R, Wang X, Shen HM (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8:634-646
20. Mendoza MC, Er EE, Zhang W, Ballif BA, Elliott HL, Danuser G et al (2011) ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell 41:661-671
21. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB et al (2003) PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 162:281-291
22. Gadea G, Sanz-Moreno V, Self A, Godi A, Marshall CJ (2008) DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol 18:1456-1465
23. Guo F, Zheng Y (2004) Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts. Mol Cell Biol 24:1426-1438
24. Nobes CD, Hall A (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81:53-62
25. Pan ZZ, Bruening W, Godwin AK (2006) Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. Int J Oncol 29:1201-1205
26. Vignjevic D, Montagnac G (2008) Reorganisation of the dendritic actin network during cancer cell migration and invasion. Semin Cancer Biol 18:12-22
27. Palm D, Lang K, Brandt B, Zaenker KS, Entschladen F (2005) In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol 15:396-404
28. Ren K, Jin H, Bian C, He H, Liu X, Zhang S et al (2008) MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem 283:35598-35605
29. Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD et al (2001) Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med 7:816-830
30. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509-514
31. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M (2009) Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29:119-123
32. Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM (2007) The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene 26:2885-2893
33. Raftopoulou M, Hall A (2004) Cell migration: rho GTPases lead the way. Dev Biol 265:23-32
34. Vial E, Sahai E, Marshall CJ (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4:67-79
35. Hong T, Grabel LB (2006) Migration of F9 parietal endoderm cells is regulated by the ERK pathway. J Cell Biochem 97:1339-1349
36. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8:393-412
37. Wang SY, Wang K, Xin Y, Lv DC (2009) Maggot excretions/secretions induces human microvascular endothelial cell migration through AKT1. Mol Biol Rep 37:2719-2725
38. Shi L, Zhao M, Luo Q, Ma YM, Zhong JL, Yuan XH et al (2009) Overexpression of PIP5KL1 suppresses cell proliferation and migration in human gastric cancer cells. Mol Biol Rep 37:2189-2198
39. Lee JS, Kim IS (2009) Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation. Mol Biol Rep 37:2149-2156
40. Guo F, Liu Y, Li Y, Li G (2010) Inhibition of ADP-ribosylation factor-like 6 interacting protein 1 suppresses proliferation and reduces tumor cell invasion in CaSki human cervical cancer cells. Mol Biol Rep 37:3819-3825
41. Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH et al (2010) Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res 70:2415-2423
42. Zhu M, Chen D, Li D, Ding H, Zhang T, Xu T et al (2012) Luteolin inhibits angiotensin ii-induced human umbilical vein endothelial cell proliferation and migration through downregulation of Src and Akt phosphorylation. Circ J 77(3):772-779
43. Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L et al (2013) Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 7:e52279
44. Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM et al (2008) Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 29:1807-1815
45. Lee WJ, Wu LF, Chen WK, Wang CJ, Tseng TH (2006) Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact 160:123-133